Phase 1 evaluation of UniFluVec: safety and reactogenicity of an intranasal universal influenza vector vaccine at two dose levels
Microbiology Independent Research Journal (MIR Journal) · 2025
DOI: 10.18527/20251216879 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbiology Independent Research Journal (MIR Journal), 2025. Verfasst von Marina Stukova und 5 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: UniFluVec is a live attenuated recombinant influenza vaccine candidate designed to enhance mucosal immunity and provide broad cross-protective responses after intranasal administration. This Phase 1 randomized, double-blind, placebo-controlled trial evaluated its safety and tolerability in healthy adults. METHODS: Sixty volunteers aged 18-49 years were randomized to receive two intranasal doses of UniFluVec (6.7 or 7.7 log10EID50) or placebo, administered 21 days apart. Safety assessments included local and systemic reactogenicity, unsolicited adverse events (AEs), serious AEs (SAEs), clinical laboratory parameters, vital signs, and evaluation of viral shedding using rapid antigen testing. RESULTS: UniFluVec was well tolerated at both dose levels. No vaccine-related SAEs or clinically significant safety signals were observed. The most frequently reported adverse events were mild local reactions – primarily nasal congestion, rhinorrhea, and sore throat – which resolved spontaneously. Systemic symptoms, including low-grade fever, headache, fatigue, and myalgia, were infrequent, transient, and predominantly mild. No vaccine-related abnormalities were detected in the hematological, biochemical, or vital-sign parameters. No influenza A virus was detected in any volunteer at any study visit according to the express test results. The reactogenicity did not increase after the second dose. CONCLUSION: UniFluVec demonstrated a favorable safety and tolerability profile in healthy adults, with no clinically meaningful adverse events reported. These findings support the further clinical development of UniFluVec as a universal influenza vaccine candidate. Clinical Trial Registration number: NCT04650971 (2020-12-03).
Zitieren
APA
Stukova, M., Zubkova, T., Buzitskaya, Z., Shurygina, A., Erofeeva, M., & Nebolsin, V. (2025). Phase 1 evaluation of UniFluVec: safety and reactogenicity of an intranasal universal influenza vector vaccine at two dose levels. Microbiology Independent Research Journal (MIR Journal). https://doi.org/10.18527/20251216879
Vancouver
Stukova M, Zubkova T, Buzitskaya Z, Shurygina A, Erofeeva M, Nebolsin V. Phase 1 evaluation of UniFluVec: safety and reactogenicity of an intranasal universal influenza vector vaccine at two dose levels. Microbiology Independent Research Journal (MIR Journal). 2025. doi:10.18527/20251216879
BibTeX
@article{Stukova2025,
author = {Stukova, Marina and Zubkova, Tatiana and Buzitskaya, Zhanna and Shurygina, Anna-Polina and Erofeeva, Mariana and Nebolsin, Vladimir},
title = {Phase 1 evaluation of UniFluVec: safety and reactogenicity of an intranasal universal influenza vector vaccine at two dose levels},
journal = {Microbiology Independent Research Journal (MIR Journal)},
year = {2025},
doi = {10.18527/20251216879}
}
EUVIMED